Communicated by H.Michel lnterleukin-4 (IL-4) represents a prototypic lymphokine (for a recent review see Paul, 1991) . It promotes differentiation of B-<:ells and the proliferation of T-and B-<:ell, and other cell types of the lymphoid system. An antagonist of human IL-4 was discovered during the studies presented here after Tyr124 of the recombinant proteinbad been substituted by an aspartic acid residue. This IL-4 variant, Y124D, bound with high affinity to the IL-4 receptor (K 0 = 310 pM), but retained no detectable proliferative activity for T -<:ells and inhibited IL-4-dependent T -cell proliferation competitively (Ki = 620 pM). The loss of efficacy in variant Y124D was estimated to be > 100-fold on the basis of a weak partial agonist activity for the very sensitive induction of CD23 positive B-<:ells. The subsitution of Tyr124 by either phenylalanine, histidine, asparagine, Iysine or glycine resulted in partial agonist variants with unaltered receptor binding atTmity and relatively small deficiencies in efficacy. These results demoostrate that high affinity binding and signal generation can be uncoupled efticiently in a Iigand of a receptor betonging to the recently identified hematopoietin receptor family. In addition we show for the fli"St time, that a powerful antagonist acting on the IL-4 receptor system can be derived from the IL-4 protein.
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Key words: drug design/partial agonists/receptor signalling lntroduction Interleukin-4 (IL-4) represents a typical immunoregulatory lymphokine (for review see Paul and Ohara, 1987; Finkelman et a/., 1990; Paul, 1991) . lt is produced mainly by activated T -cells and mast cells and has a wide range of biological activities on various cell types of the lymphoid system. B-cells are stimulated in vitro to express dass II major histocompatibility complex (MHC II) molecules, the IgE low affinity receptor (FcERII, CD23) and immunoglobulins dass E and G 1. DNA synthesis is induced in activated B-cells, as weil as in mature T -cells, foetal thymocytes, mast cells and others.
Mice treated with neutralizing antibodies directed against IL-4 or against the IL-4 receptor (Finkelman et al. , 1990; Urban,Jr et al., 1991) , as well as mice bearing an inactivated IL-4 gene (Kühn et al. , 1991) , are unable to produce lgE and show reduced serum Ievels of IgG 1 after challenge with © Oxford University Press the relevant stimuli. This indicates a physiological role of IL-4 at least in the regulation of lgE Ievels, most likely by acting as an isotype switching factor. Consequently, IL-4 may exert a pathophysiological role in the generation of disease states, as for example hyper-lgE syndrome or IgEmediated allergic conditions (see Finkelman et al., 1990; Tepper et al., 1990) .
IL-4 function is mediated by its binding to plasma membrane receptors occurring at the relatively small numbers of 150-2500 molecules per target cell (Cabrillat et al. , 1987; Park et al. , 1987) . A single dissociation constant of -100 pM has been determined for this interaction. The IL-4 receptor probab1y comprises only a single polypeptide chain of -800 amino acid residues as suggested by chemical crosslinking experiments using 125 1 Iabelied IL-4 (Mos1ey et al. , 1989; Galizzi et al. , 1990; Harada et al., 1990; ldzerda et al., 1990) . Binding to IL-4 in vitro is not influenced by structural elements apart from the extracellular portion of the receptor, since similar dissociation constants were found for association with IL-4 with the entire receptor and only the Iigand binding domain in the case of both the mouse and the human protein (Maliszewski et al. , 1990; Garrone er al. , 1991) . At present it is unclear if a second protein aggregates with the receptor after IL-4-induced activation. The IL-4 receptor is evolutionarily related to the large family of hematopoietin receptors, induding receptors (or receptor subunits) for interleukins-2, 3, 4, 5, 6 and 7, for GM-and G-CSF and also for erythropoietin, growth hormone and prolactine (Bazan, 1990a,b; Cosman et al., 1990) . Allthese proteins show particular homologies in the amino acid sequence of their extracellular Iigand binding domains.
NMR studies revealed a three-dimensional structure of human IL-4 comprising a four-helix bundle motif with an up-up-down-down connectivity (Redfield et a/. , 1991) similar to both human and porcine growth hormone (AbdelMeguid er a/. , 1987; De Vos et al. , 1992) . Other ligands binding to members of the haematopoietin receptor family also appear tobe helically organized proteins (see Bazan, 1990a,b) . The crystal structure ofhuman IL-2 shows a fourhelix bundle (Brandhuber et al. , 1987) albeit with a connectivity different from IL-4. The amino acid sequences of these ligands display no clear homo1ogies. A puzzling similarity, however, is apparent in the pattem of amino acid residues forming one surface of a putative amphipathic helix at the C-terminus ofthese proteins (Sanderson er al., 1988; see Bazan, 1990b) . Sequence positions involved in receptor binding have been identified in several 1igands of the haematopoietin receptor family, e.g. in IL-2 (Collins et al., 1988; Weige1 et al., 1989; Zurawski and Zurawski, 1989) , growth hormone (Cunningham and WeHs, 1991; Cunningham et al., 1991) , GM-CSF and IL-5 (Shanafelt et al., 1991) . Amino acid residues involved in signal generation, however, have been more difficu1t to identify. In order to address this issue, contributions of particular amino acids to receptor affinity and biological activity, respectively, have to be distinguishable. As yet, uncoupling of receptor binding from biological effects has been observed to some extent only in the case of certain mutant derivatives of both human and murine IL-2 (Liang et al., 1988; Zurawski et al. , 1990 ).
Recently we have generated a set of mutant variants of human IL-4 with single substitutions at the positions of all cysteinyl and aromatic residues (Kruse et al., 1991) . One of these variants, Y124D, was completely inactive even at micromolar concentrations during a T-cell proliferation assay. Subsequently, we realized that variant Y124D efficiently inhibits IL-4 induced T -cell proliferation. This promoted the generation of IL-4 variants in which Tyr124 was substituted by residues differing in size, polarity or charge, respectively. The receptor binding affinity of these isolated mutant proteins was determined, as weil as their biological activities in two in vitro assays differing in sensitivity by nearly two orders of magnitude. The results of these experiments indicated that the nature of the side chain at position 124 of human IL-4 dramatically affects signal generation and biological activity, while the influence on receptor binding is marginal.
The demonstration of the feasibility to obtain an efficient antagonist of the IL-4 receptor system has several important implications. First, inhibitory IL-4 variants represent potential drugs helpful for example in the treatment of lgEmediated diseases (see e.g. Pinkelman et al., 1990; Paul, 1991) similar to therapeutic monoclonal antibodies against IL-4 or to the soluble extracellular IL-4 receptor domain (Maliszewski et al. , 1990; Garrone et al. , 1991) . Secondly, antagonistic ligands may prove valuable tools for the investigation of IL-4 receptor-mediated signal transducing mechanisms. Thirdly, considering the homologies and similarities mentioned above, it is an intriguing possibility that similar antagonistic variants will be found for other ligands of this receptor family (see also Zurawski et al., 1990) .
Results

Reduced efficacy of IL4 variants in T -cell proliferation
Recombinant human IL-4 promoted DNA synthesis in prestimulated T -cells with a half-maximal response at a concentration (EC 50 ) of 230 pM (Figure 1 ). Substitution of Tyr124 by aspartic acid near the C-terminus of the 129-residue D-4 resulted in the mutant protein Y124D, which bad no measurable activity in the T -cell proliferation assay (see also Kuruse et al., 1991) . Substitution of Tyr124 by a series of other amino acid residues caused less pronounced alterations. As the mutant protein Y124F bad the same bioactivity as wild type IL-4 (see Table I for statistical evaluations), the hydroxyl group ofTyr124 is not essential. His124 caused a small but significant reduction of the maximal response. Asparagine, Iysine or glycine at this position reduced the potency to 29-13% ofwild type IL-4. A comparison ofmutant proteins Y124N and Y124D clearly demonstrated that the introduction of a negative charge caused the most dramatic effect on IL-4 activity. Remarkably, the half-maximal response of the residual activity (EC 50 ) of the mutant proteins remained within the same concentration range ( 130-230 pM) as found for wild type IL-4. This is a typical characteristic of partial agonists for which binding and signal generation (efficacy) are partially uncoupled (Ruffolo,Jr, 1982; Black, 1989) . The unaltered EC 50 values for the variants further suggest that the response is limited by receptor occupancy (Ruffolo,Jr, 1982) . Mutantproteins affected in receptor binding (see e.g.
Collins et al., 1988; Weigel et al., 1989; Zurawski and Zurawski, 1989; Cunningham and Wells, 1991; Cunningham et al. , 1991; Shanafelt et al. , 1991) show a different behaviour such that they produce a maximal response similar to the wild type if applied in sufficient concentrations.
Partial agonism of IL-4 variants in B-eeil differentiation
Compared with the T -cell proliferation assay, much lower concentrations of IL-4 were sufficient to stimulate B-cells for the induction of CD23 (FceRII), the low affinity IgE receptor (Kikutani et al., 1986; DeFrance et al., 1987) .
After stimulation, the number of CD23 positive cells increased with EC 50 of -0.4 pM for IL-4 ( Figure 2A ) (see also Solari et al., 1989) . In this very sensitive assay, mutant protein Y124D behaved as a partial agonist. The number of B-cells that were stimulated by Y124D to express CD23 was up to 45% ofthat found for wild type IL-4, with an EC 50 of 210 pM. Very high IL-4 concentrations did not increase the number of CD23 positive cells further, but stimulated higher mean CD23 expression in the responding cells as also determined by FACS analysis. The mean EC 50 was 5 pM IL-4 in different experiments (see Table 1 ). Mutant protein Y124D induced a maximal response of8% compared with wild type IL-4 ( Figure 2B ). Half-maximal response occurred at 310 pM Yl24D. These results clearly established that the mutant protein Y124D has a very weak partial agonist activity that was detectable only in the sensitive Beeil assay. The effective concentration for the half-maximal response of 210 pM and 310 pM, however, was in the range of the EC 50 found for IL-4 and the other mutant proteins in the T -cell system. Variant Y 1240 induced a maximal number of CD23 positive B-cells (99%) and a maximal mean CD23 content (77%) similar to IL-4 ( = 100%). The EC 50 for these responses, however, were found tobe increased several-fold to -5 and 40 pM, respectively (Figures 2A and B T -cell proliferation assay (see Tables I and II) . Thus, the properties of partial agonist Y l24G are consistent with an IL-4 receptor system in B-cells operating at low occupancy during CD23 induction. In this case, the EC 50 values for a partial agonist are expected to increase proportionally to the loss of efficacy (Ruffolo,Jr, 1982) . The CD23 positive cells represented 67% of the total cells analysed by FACS. This percentage remained constant at all saturation Ievels. Thus, the induction of the number of CD23 positive cells and the induction of mean CD23 content most probably reflected two aspects of the same process in the same ceil population. Of two alternatives-either each induced cell immediately develops a fuil CD23 content or the whole population is first induced to develop a low CD23 content which upon higher stimulation is increased-the second is consistent with the observed data.
Competitive receptor binding
The dose-response curves suggest that the amino acid exchanges at position 124 did not dramatically alter the receptor affinity of the mutant proteins compared with wild type IL-4. This has been corroborated by radioligand receptor binding experirnents (Figure 3) . IL-4, as weil as the mutant proteins studied here, competed efficiently with iodinated IL-4 for the IL-4 receptors present on the Blymphoma ceilline Raji (Cabrillat et al., 1987; Parket al., 1987) (Table II) . (Unfortunately, the large numbers of activated B-ceils necessary for radioligand binding could not routinely be obtained from human spieen).
The concentration of 1 nM [ 125 I]IL-4 during the competitive binding experimentswas -10-fold higher than the dissociation constant. Thus, the K 0 of the competing ligands could not be determined from the IC 50 (Munson, 1983) . The K 0 of [ 125 I]IL-4 detennined independently (see Materialsand methods) was 91 pM for the B-lymphoma cells and 81 pM for the PHA-activated T-cells. Assuming a receptor dissociation constant K 0 of -100 pM for IL-4 (see also Cabrillat et al., 1987; Parket al., 1987) Activated human B-and T -cells both expose 500-1000 molecules of IL-4 receptor at their surface showing a K 0 of -100 pM in terms ofiL-4 binding (see above). Therefore the proliferative response ofT -cells appears to closely follow the receptor occupancy. Assuming that in the B-eeil assays the biological response is sole1y mediated by the receptor with a K 0 of 100 pM, the induction of CD23 requires the occupancy of only a few percent of the receptors by IL-4. We suggest that only in case of the 'emasculated' (Black, 1989) Y124D mutant protein, the receptor bad to be maximally saturated in order to generate a small partial response. It remains unclear, however, if the assay periods IC 50 and Ki values were distributed log normal. The IC 50 of the variants were related to the IC 50 of IL-4 as 100%. Numbers in brackets were calculated from log IC 50 ± log SD or log Ki ± log SO.
K 0 values ± SD were calculated from Scatchard analyses. 8 Tonsillar B-cells were used in one experiment.
of several days eonventionally used allow for a straight eomparison between receptor occupancy and response.
Antagonist activity of /L-4 variant Y124D
The results presented above Iead to the prediction that the mutant protein Y124D functions as a pure antagonist in the T -cell system and as a partial antagonist of IL-4 in the mueh more sensitive B-cell system. This has been actually demonstrated by competition experiments (Figure 4 ). IL-4-stimulated proliferation of T -eells was competitively inhibited by mutant protein Y124D ( Figure 4A ). From the apparent EC 50 in the presenee of different concentrations of Y124D an inhibitor constant Ki of 620 pM eould be calculated (see Table II ). A similar Ki of 810 pM was determined during competititon of IL-4-dependent CD23 induction on B-cells ( Figure 4B ). lncluded in Table ll is also the inhibitory eonstant Ki of 1000 pM for the induction of the number of CD23 positive B-cells ( Figure 4C ). The latter value shows a high variability due to the pronounced partial agonist aetivity of variant Y124D during this response (45%). For the partial agonists Y124G, Y124N, Y124K and even for Y124H, and incomplete inhibition of IL-4 aetivity was established in the T -cell proliferation assay down to the Ievel determined by their respective partial agonist aetivities (see Figure 1) . The ealeulated Ki values werein the range of 200 pM (data not shown).
A comparison of the dose-response curves in Figure 4A , B and C shows that the slopes of the T -cell responses are steeper. The same difference was observed for the experimental results presented in Figures 1 and 2A, 
and B. The binding curve of [
125 I]IL-4 to B-lymphoma cells or activated T -cells has a slope with a caleulated Hili coefficient of 0.81-1.15 (data not shown) similar to the B-eeil responses (0.91-1.4). The Hili coeffieient calculated for the slope of the dose-response curve for IL-4-dependent T -cell proliferation is -2-fold higher (2 -2. 7). In the competitive inhibition experiments, the slope was reduced -2-fold in the presence of antagonist Yl24D, bothin the T-eell (1.3-1.5) and in the B-eeil (0.5 -0.6) assays. The significance of these differenees is still unclear. They might also indicate specifie aspeets of receptor activation, but we cannot presently rule out an origin from experimental eonditions. 
Discussion
The results presented here indieate conclusively that Tyr 124 of IL-4 is of crucial irnportance for the poteney of the lymphokine for signal generation, but not for the binding of IL-4 to its receptor. Whereas biologieal aetivity was severely impaired in several substitution mutants at position 124 (see below), binding of this variant ligands to IL-4 receptor was not at all or only marginally affected. As eompiled in Tables I and ll , this is shown first by radioligand reeeptor binding experirnents using the IL-4 receptor of the B-lymphoma cell line Raji (Park et al., 1987) , or of both activated T-and B-cells, secondly, by determining the EC 50 of the partial agonist activities in both the B-eeil and the Teell assay and thirdly, by determining the competitive inhibitor constants, Ki, in both eellular systerns. The impairment of biological activity, i.e. the loss of efficacy of IL-4, strongly depends on the nature of the side ehain introdueed at position 124. In the T -cell assay, efficaey is roouced -5-fold with side chains of asparagine, Iysine and glycine, respectively, and > 1 00-fold with an aspartyl side chain (see Table 1 ). Interestingly, the loss of efficacy appears to be less pronouneed during the B-eeil differentiation assays. This, however, corresponds to the -40-fold lower EC 50 of IL-4 for the mean CD23 induction or the 500-fold lower EC 50 for induction of CD23 positive cells when compared with the T -cell response. These apparent discrepancies in IL-4 efficacy can be explained in terms of receptor occupancy. The EC 50 of -200 pM for T -cell proliferation is similar to the IL-4 receptor dissociation constant. Accordingly, this response may be limited by the number of activated receptors. The B-cell response appears to be limited by a signaHing step following receptor activation. This step then would determine the EC 50 of 5 pM (0.4 pM) in these processes, which correspond to a receptor occupancy of -5% (mean CD23 content) or 0.4% (number of CD23 positive cells). The
Human IL-4 antagonist mutant proteins calculation and its underlying assumptions are detailed in Materials and methods. The lower efficacy of the IL-4 variants can thus be partially compensated for by higher receptor saturation. In case of mutant protein Y124D maximal response is 8% ( 45%) with an EC 50 or 310 pM (210 pM) for mean CD23 induction (CD23 positive cells). According to these data, the loss of efficacy is 125-to 300-fold. During the T -cell proliferation assays, the mean error of the control was 0.5% of the maximal response of IL-4. The responses ofvariant Y124D were within the mean error ofthe control. Thus, the efficacy ofY124D is at least 200-fold lower than that of IL-4 in this system. Although these calculations are rough estimates derived from long term assays, measuring complex proliferation and differentiation processes, at least they should provide information conceming the upper Iimit. (An alternative explanation of the results involving a very small subpopulation of receptors, e.g. 20-50 molecules/cell, with a very low dissociation constant in the range of 1 pM in the B-cells appears rather unlikely, since the antagonist Y124D inhibits with the sarne inhibitory constant of 620-1000 pM both B-and T-cells.)
The identification of a whole panel of partial agonists suggests that the residue at position 124 is directly involved in signal generating interactions. The amino acid exchange in mutant protein Y124D, however, produces an unexpectedly large effect. Thus, additional conformation effects appear tobe possible in this case. It may be relevant in this respect that variant Y124D does not easily crystallize (T.Müller and W.Sebald, unpublished observation) in contrast to IL-4 (Cook et al., 1991) . It remains to be established if further residues in the IL-4 molecule, together with Tyr124, form a site distinct from a IL-4 receptor binding site, which is involved in signal generation. According to the available structural information (Redfield et al. , 1991; see also Diederichs et al. , 1991) residues at the C-terminal end of helix D are close to Tyr124. Cys127 forms a disulfide bond to Cys3. Thus, side chains of helix A may also be in proximity to Tyr124. It is interesting to note that for human GM -CSF, which has the same fold as IL-4, a receptor binding site was postulated consisting of two peptide stretches centered around Arg24 (helix A) and Met79 (helix C) (Diederichs et al. , 1991) . According to the GM-CSF crystal structure, this binding site would be spatially far away from the C-terminus of helix D.
Tyr124 of human IL-4 is found at the corresponding position of murine IL-4 (Sanderson et al., 1988) . It occurs at the end ofhelix D (Redfield et al., 1991) , only six residues away from the C-terminus. It has been noted (Bazan, 1990b; Sanderson, 1988 ) that this C-terminal segment has features in common with other known ligands of the haematopoietin receptor family. Amino acid substitutions of Glu141 of murine IL-2 (Zurawski et al., 1990) , whose position appears tobe equivalent to Tyrl24 of human IL-4, yielded a series ofpartial agonists. In particular, murine IL-2 variant Q141D was inactive or only weakly active in proliferation assays using various celllines. However, high affinity bindingwas lost and no competitive inhibition of IL-2-dependent proliferation of HT2 cells could be found even at a 5 x 10 ( class IV), could be grouped into four classes according to their differing partial agonist activities. This is unlike the variants of human IL-4, where substitutions of Tyr124 by asparagine, Iysine and glycine produced very similar agonist activities (see Figure 1 , Table 1 ). Thus, it remains unclear in how far the generation of partial agonism by an aspartyl side chain at the human IL-4 Y124 and at the murine IL-2 Q141 positions indicates comparable structural requirements.
Two non-overlapping binding sites were identified in human growth hormone (Cunningham and Wells, 1991; Cunningham et al., 1991; De Vos et al., 1992) This could argue for a structural separation of two independent functional sites in the IL-1 protein. lnterestingly, however, significant differences exist among those amino acid residues ofiL-1cx, IL-1ß and ll-1Ra that probably provide the contact points in each receptor-Iigand complex. Accordingly, an apparently unaltered receptor affinity of an engineered antagonist might also result from multiple compensating effects and it does not necessarily indicate a structural independence of the two Iigand domains that bind or activate the receptor, respectively.
Especially for IL-1cx variant D141G pure agonist or partial agonist activities were established in various cellular responses (Yamayoshi et al., 1990) , which resemble our results with human IL-4 variant Y124D. Considering the fundamental structural differences between IL-1 and IL-4, as well as between their respective receptors, it is interesting to speculate that the occurrence and the straight forward identification of high affinity antagonists in both systems is correlated with a single chain composition of both the receptors.
Other more complex receptor systems may put more stringent constraints on structural modifications ofthe Iigand. In the multichain IL-2 receptor system the intrinsically high K 0 of 70 nM of the ß subunit (the homologue of the IL-4 3242 receptor) was found to decrease to 5 pM in the presence of the cx subunit (see Ringheimet al., 1991) . A decreased K 0 of 1.2 nM was observed in YT cells due to the presence of a still poorly defined 'Y subunit. Interestingly, IL-2 variants affected in cx subunit binding showed an apparently unaltered EC 50 in the biological assays (Weigel et al., 1989; Zurawski and Zurawski, 1989; Ju et al., 1991) . For the explanation of this puzzling behaviour a model was recently proposed (Grant et al., 1992) according to which the cx subunit contributes several functions to IL-2-mediated signalling through the high affinity IL-2 receptor system. Interestingly, the partial agonist and antagonist variants affected at position Gln141 ofmurine IL-2 (Zurawski et al., 1990) were described tobe deficient in ' Y subunit interactions. They inhibited efficiently, however, the IL-2 variants defective in cx subunit binding. Possibly, the interaction of the ' Y subunit and the ß subunit is critical for receptor activation and any disturbance of this interaction will reduce both receptor binding and receptor activation. This complex subunit interplay in the IL-2 receptor system therefore complicates its analysis, but may also provide special advantages for the engineering of selective agonists (see Zurawski, 1991) .
Increasing evidence supports the view that the formation of receptor homodimers or the forming of heterooligomers represents an important step in receptor transmembrane signalling (see Schlessinger, 1988; Williams, 1989; UHrich and Schlessinger, 1990) . This Ieads to the question how the Iigand triggers this aggregation. 'Allosteric receptor oligomerization' (Schlessinger, 1988) , proposedas a model for tyrosine kinase receptors, involves two conformations of the extracellular domain. Only the high affinity Iigand binding conformation forms oligomers. Bridging of two receptor proteins by a single Iigand molecule represents another possible mechanism for oligomerization (Ullrich and Schlessinger, 1990; Cunningham et al., 1991) supported by the recent finding that growth horrnone forms a 1 :2 complex with the isolated extracellular receptor domain. For the IL-4 receptor, no evidence for the occurrence of dimers or oligomers has as yet been provided. A single class of IL-4 receptor or IL-4 binding protein has been identified so far, exhibiting one homogeneous dissociation constant of -100 pM. lt remains to be established whether IL-4 receptor signalling involves the formation of a homodimer or whether the aggregation with other hitherto unknown proteins is necessary. The availability of antagonist IL-4 variants will open up new ways to address the question of which mechanisms operate during IL-4 receptor signalling.
Materials and methods
Production of /L-4 mutsnt proteins
Human IL-4 and mutant proteins were produced in Escherichia coli, subjected to a renaturation step and highly purified by CM-Sepharose 68 chromatography followed by HPLC (Weigel er al., 1989; Kruse er al., 1991) . By means of in virro mutagenesis Tyrl24 (Kruse er al., 1991) had been replaced by phenylalanine, histidine, asparagine, Iysine, glycine or aspartic acid, respectively, to generate mutant proteins Yl24F, YI24H, YI24N, YI24K, YI24G and YI24D. The mutated genes recloned into the expression plasmid were sequenced in both directions (373A DNA Sequencer, Applied Biosystems) to confirm the mutation. Protein concentration was determined by measuring absorbance at 280 nm. It was assumed that I mg IL-4/mJ (50% Acetonitril and 0.1% trifluoracetic acid) yields an absorbance of I at 280 nm (E~ilh% = 1). For protein measurements of variants deficient in Tryl24, the absorbance at 280 nm was multiplied by a factor of 1.15.
